Agios Pharmaceuticals Inc (AGIO) Stock Analysis
Verdict: HOLD
Mitapivat's priority review in Sickle Cell Disease transforms AGIO from a niche player to a multi-indication rare disease powerhouse.
Investment score: 64/100
Analysis as of
Is Agios Pharmaceuticals Inc stock worth reviewing? The TradeMates thesis
Agios is transitioning into a high-growth phase following the FDA's acceptance of mitapivat for Sickle Cell Disease. With a $1.3B asset base and a priority review date in November, the risk-reward remains favorable despite the recent 50% run.
7-factor investment score
- Valuation: 45/100 (weight 20%)
- Financial Health: 75/100 (weight 15%)
- Technical Momentum: 85/100 (weight 15%)
- Earnings Quality: 70/100 (weight 15%)
- Insider Sentiment: 50/100 (weight 10%)
- Analyst Consensus: 60/100 (weight 10%)
- Risk-Adjusted Return: 55/100 (weight 15%)
Agios Pharmaceuticals Inc opportunities and risks
What speaks for AGIO
- Sickle Cell Disease PDUFA Catalyst
What speaks against AGIO
- Binary Regulatory Risk (Nov 1)
Peers and competitors
| Ticker | P/E | P/S | EV/EBITDA | Gross margin | Net margin | FCF yield |
|---|---|---|---|---|---|---|
| AGIO | n/a | 39.6x | n/a | 82.1% | -639.8% | -14.7% |
| BCRX | n/a | 2.6x | n/a | 18.9% | -51.7% | 12.7% |
| IMNM | n/a | 580.7x | n/a | -1161.9% | -5593.8% | -8.8% |
| MLYS | n/a | 0.0x | n/a | 0.0% | 0.0% | -6.8% |
| NRIX | n/a | 29.5x | n/a | -139.4% | -411.4% | -12.9% |
| SLS | n/a | 0.0x | n/a | 0.0% | 0.0% | -1.1% |
| Peer median | n/a | 2.6x | n/a | 0.0% | -51.7% | -6.8% |
Frequently asked questions about Agios Pharmaceuticals Inc (AGIO)
Is AGIO stock a good investment?
The TradeMates model rates Agios Pharmaceuticals Inc as HOLD with an investment score of 64/100. Agios is transitioning into a high-growth phase following the FDA's acceptance of mitapivat for Sickle Cell Disease. With a $1.3B asset base and a priority review date in November, the risk-reward remains favorable despite the recent 50% run. This is algorithmic model output, not personal investment advice.
Is AGIO stock a buy?
The TradeMates model verdict for AGIO is HOLD with an investment score of 64/100. Treat this as a model signal to review, not a personal buy recommendation.